Clinical Trials Browser

lenvatinib × Endocrine × 30 days × Clear all

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Phase 2 Active not recruiting

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Phase 2 Recruiting

Neuroendocrine Tumors

NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Differentiated Thyroid Cancer